[Analysis of Clinical Characteristics in 49 Patients of Lung Cancer Combined with Interstitial Lung Disease].
- 1Department of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China.
- 2Department of Pulmonary and Critical Care Medicine, Fuxing Hospital, Capital Medical University, Beijing 100038, China.
Abstract
Background
The patients of lung cancer combined with interstitial lung disease (LC-ILD) account for a high proportion, and their prognosis is poor. Currently, no standard treatment regimen had been established for this population. This study aimed to summarize the clinical characteristics and treatment outcomes of patients with LC-ILD, and to explore factors associated with marked ILD progression under different tumor treatment strategies.Methods
The clinical characteristics, tumor treatment, and follow-up data of 49 LC-ILD patients hospitalized in the Department of Pulmonary and Critical Care Medicine at Peking Union Medical College Hospital from January 2018 to December 2024 were collected. The efficacy and follow-up outcomes of different treatment modalities were observed; the survival analysis was performed, and the potential influencing factors for the significant progression of ILD were analyzed.Results
LC-ILD is most commonly of the usual interstitial pneumonia (UIP) pattern, with tumors frequently located in fibrotic regions. The median progression-free survival (PFS) was 7.0 months for advanced non-small cell lung cancer (NSCLC) and 4.0 months for small cell lung cancer (SCLC). Of the 36 patients with completed follow-up and treatment, 10 showed radiographic progression of interstitial lesions, with 4 deaths occurring in this subgroup. Logistic regression analysis indicated that radiotherapy was significantly correlated radiological progression of ILD (P<0.05).Conclusions
For patients with LC-ILD, individualized evaluation including chest high resolution computed tomography and pulmonary function test (particularly diffusing capacity) should be performed before initiating therapy. The therapeutic approach should balance efficacy and safety, and special attention should be given to the risk of radiological progression of ILD associated with radiotherapy.
Related
- Clinical Characteristics and Outcomes of Anti-MDA5 Antibody-Associated Interstitial Lung Disease: A Single-Center Retrospective Cohort Study from an Integrated Advanced Lung Disease and Lung Transplant Program in the US
- Clinical characteristics and mortality risk of sarcopenia in interstitial lung disease: a systematic review and meta-analysis.
- Short-term clinical efficacy and recorded adverse events of semaglutide combined with dapagliflozin in patients with type 2 diabetes mellitus and chronic kidney disease
- Clinical Outcomes of Combined TAVR-PCI Versus SAVR-CABG in Patients with Aortic Stenosis and Coronary Artery Disease: A Systematic Review and Meta-Analysis
- Predictive value of a combined model based on immune indicators and clinical characteristics for the prognosis of patients with primary myelofibrosis
BibTeX
@article{zhao2026analysis,
title = {{[Analysis of Clinical Characteristics in 49 Patients of Lung Cancer Combined with Interstitial Lung Disease].}},
author = {Jing Zhao and Lihua Zhao and Xiaoxing Gao and Xiaoyan Liu and Yan Xu and Minjiang Chen and Wei Zhong and Mengzhao Wang},
journal = {Zhongguo fei ai za zhi = Chinese journal of lung cancer},
year = {2026},
month = aug,
doi = {10.3779/j.issn.1009-3419.2026.106.25},
url = {https://europepmc.org/article/MED/42896972},
note = {CC BY},
}
RIS
TY - JOUR
TI - [Analysis of Clinical Characteristics in 49 Patients of Lung Cancer Combined with Interstitial Lung Disease].
AU - Jing Zhao
AU - Lihua Zhao
AU - Xiaoxing Gao
AU - Xiaoyan Liu
AU - Yan Xu
AU - Minjiang Chen
AU - Wei Zhong
AU - Mengzhao Wang
PY - 2026
DA - 2026/08/01
JO - Zhongguo fei ai za zhi = Chinese journal of lung cancer
DO - 10.3779/j.issn.1009-3419.2026.106.25
UR - https://europepmc.org/article/MED/42896972
AB - Background The patients of lung cancer combined with interstitial lung disease (LC-ILD) account for a high proportion, and their prognosis is poor. Currently, no standard treatment regimen had been established for this population. This study aimed to summarize the clinical characteristics and treatment outcomes of patients with LC-ILD, and to explore factors associated with marked ILD progression under different tumor treatment strategies.Methods The clinical characteristics, tumor treatment, and follow-up data of 49 LC-ILD patients hospitalized in the Department of Pulmonary and Critical Care Medicine at Peking Union Medical College Hospital from January 2018 to December 2024 were collected. The efficacy and follow-up outcomes of different treatment modalities were observed; the survival analysis was performed, and the potential influencing factors for the significant progression of ILD were analyzed.Results LC-ILD is most commonly of the usual interstitial pneumonia (UIP) pattern, with tumors frequently located in fibrotic regions. The median progression-free survival (PFS) was 7.0 months for advanced non-small cell lung cancer (NSCLC) and 4.0 months for small cell lung cancer (SCLC). Of the 36 patients with completed follow-up and treatment, 10 showed radiographic progression of interstitial lesions, with 4 deaths occurring in this subgroup. Logistic regression analysis indicated that radiotherapy was significantly correlated radiological progression of ILD (P<0.05).Conclusions For patients with LC-ILD, individualized evaluation including chest high resolution computed tomography and pulmonary function test (particularly diffusing capacity) should be performed before initiating therapy. The therapeutic approach should balance efficacy and safety, and special attention should be given to the risk of radiological progression of ILD associated with radiotherapy.
SN - 1009-3419
SN - 1999-6187
ER -